Gepotidacin
Blujepa (gepotidacin) is a small molecule pharmaceutical. Gepotidacin was first approved as Blujepa on 2025-03-25.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Blujepa
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| blujepa | New Drug Application | 2025-03-25 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| urinary tract infections | EFO_0003103 | D014552 | N39.0 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
22 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | — | — | 2 | 4 | — | — | 6 |
| Communicable diseases | D003141 | — | — | — | 2 | 4 | — | — | 6 |
| Urinary tract infections | D014552 | EFO_0003103 | N39.0 | — | 1 | 4 | — | — | 5 |
| Gonorrhea | D006069 | DOID_7551 | A54 | 1 | 1 | 1 | — | — | 3 |
| Cystitis | D003556 | EFO_1000025 | N30 | — | 1 | 2 | — | — | 3 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bacterial infections | D001424 | — | A49 | 8 | 2 | — | — | — | 10 |
| Bacterial skin diseases | D017192 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Respiratory tract infections | D012141 | — | J06.9 | 5 | — | — | — | — | 5 |
| Renal insufficiency | D051437 | — | N19 | 1 | — | — | — | — | 1 |
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Gepotidacin |
| INN | gepotidacin |
| Description | Gepotidacin (INN) is an experimental antibiotic that acts as a topoisomerase type II inhibitor. It is being studied for the treatment of uncomplicated urinary tract infection (acute cystitis) and infection with Neisseria gonorrhoeae (gonorrhea), including multidrug resistant strains.
|
| Classification | Small molecule |
| Drug class | antibiotics, DNA gyrase and topoisomerase IV inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=c1ccc2ncc(=O)n3c2n1C[C@H]3CN1CCC(NCc2cc3c(cn2)OCCC3)CC1 |
Identifiers
| PDB | — |
| CAS-ID | 1075236-89-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3317856 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB12134 |
| UNII ID | DVF0PR037D (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 391 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use